Potential Immunotherapeutics for Immunosuppression in Sepsis.
10.4062/biomolther.2017.193
- Author:
Jinwook SHIN
1
;
Mirim JIN
Author Information
1. Department of Microbiology, College of Medicine, Inha University, Incheon 22212, Republic of Korea.
- Publication Type:Review
- Keywords:
Sepsis;
Immunosuppression;
Immune modulators;
Immunotherapy;
Precision medicine;
Theranostics
- MeSH:
Apoptosis;
Critical Care;
Emergencies;
Humans;
Immune System;
Immunosuppression*;
Immunotherapy;
Mortality;
Opportunistic Infections;
Precision Medicine;
Sepsis*;
Theranostic Nanomedicine
- From:Biomolecules & Therapeutics
2017;25(6):569-577
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sepsis is a syndrome characterized by systemic inflammatory responses to a severe infection. Acute hyper-inflammatory reactions in the acute phase of sepsis have been considered as a primary reason for organ dysfunction and mortality, and advances in emergency intervention and improved intensive care management have reduced mortalities in the early phase. However it has been recognized that increased deaths in the late phase still maintain sepsis mortality high worldwide. Patients recovered from early severe illness are unable to control immune system with sepsis-induced immunosuppression such as immunological tolerance, exhaustion and apoptosis, which make them vulnerable to nosocomial and opportunistic infections ultimately leading to threat to life. Based on strategies to reverse immunosuppression, recent developments in sepsis therapy are focused on molecules having immune enhancing activities. These efforts are focused on defining and revising the immunocompromised status associated with long-term mortality.
